ClinicalTrials.gg
CompletedNCT02587325Updated Nov 25, 2024Results posted

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

A Phase 1 interventional study of nab-sirolimus in Pulmonary Hypertension, sponsored by Aadi Bioscience, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Aadi Bioscience, Inc. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models. nab-Sirolimus (also known as ABI-009, nab-rapamycin) is an albumin-bound mTOR inhibitor with improved penetration in lung tissue.

Read the detailed description

nab-Sirolimus, an mTOR inhibitor, is a novel formulation of albumin-bound sirolimus nanoparticles and has produced encouraging results in oncology at doses up to 100 mg/m2 given once weekly IV. This study is aimed to determine the optimal clinial dose of once weekly IV nab-sirolimus in patients with PAH and safety of 16 weeks of therapy (Phase 1, Dose finding Safety Part) followed optionally by up to 32 weeks of therapy (Extension Part).

02

Conditions studied

  • Pulmonary Hypertension
03

In context

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

This study's enrollment of 15 is below the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.

Browse Hypertension, Pulmonary studies →

Lead sponsor

Aadi Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age >18 years old with a current diagnosis of WHO Group 1 PAH including idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial hypertension (HPAH), drug and toxin induced PAH, or PAH associated with connective tissue disease, or congenital heart defects (repaired greater than 1 year prior to Screening)
  • Must meet following hemodynamic definition prior to initiation of study drug

    • Mean PAP of ≥ 25 mm Hg
    • PCWP or left ventricular end diastolic pressure (LVEDP) of ≤ 15 mm
    • PVR > 5 mmHg/L/min (Woods unit)
  • Functional class II or III according to the WHO set forth at the Dana Point Classification 2008 Meeting
  • On 2 or more specific standard PAH therapies (for ≥ 8 consecutive weeks and at stable dose for ≥ 4 consecutive weeks) unless documented inability to tolerate 2 standard therapies
  • Meet the following criteria determined by pulmonary function tests completed no more than 24 weeks prior to screening, performed with or without bronchodilation:

    • (FEV1) ≥ 55% of predicted normal
    • FEV1:forced vital capacity (FVC) ratio ≥ 0.60
  • 6MWD ≥150 meters and ≤450 meters
  • Negative serum pregnancy test
  • Female of childbearing age either surgically sterilized or using acceptable method of
  • Ability to provide written by the patient or legal guardian

Exclusion criteria

Exclusion criteria:

  • History of heart disease including (LVEF) ≤ 40% or valvular constrictive or atherosclerotic heart disease (myocardial infarction, angina, cerebrovascular accident)
  • History of in 2 years prior to enrollment
  • Pulmonary hypertension (PH) belonging to groups 2 to 5 of the 2013 Nice classification
  • Current or recent (\< 3 months) use of inotropic or vasopressor agents for the treatment of PAH
  • Recent (\< 2 months) PAH related hospital admission
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (eg, azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics
  • Uncontrolled diabetes mellitus as defined by >8% despite adequate therapy
  • Uncontrolled hyperlipidemia (serum triglyceride ≥300 mg/dL)
  • Serum cholesterol ≥350 mg/dL
  • Surgery within 3 months of start date of study drug
  • Baseline cytopenias:

    • ≤ 1.5 x 109/L
    • ≤ 9 g/dL
    • count \< 100,000/mm3
  • Baseline liver disease: /AST, total , alkaline phosphatase >1.5 x
  • Baseline renal disease: creatinine >1.5 ULN and/or (Cockcroft formula) ≤ 30 mL/min
  • Inability to attend scheduled clinic visits
  • Prior use of study drug within previous 6 months from enrollment
  • Previous lung transplant
  • Naïve to available standard PAH therapy
  • Concomitant genetic or acquired diseases (such as , AIDS)
  • Uncontrolled intercurrent illness that in the opinion of the investigator would limit compliance and tolerance to study requirements (eg, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, uncontrolled hypertension, coronary artery disease, or psychiatric illness/social situations)
  • Concomitant enrollment in another treatment protocol for PAH
  • Use of strong inhibitors and inducers of within the 14 days prior to receiving the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to receiving the first dose of ABI-009
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Nab-Sirolimus Dose Cohort 1

    nab-Sirolimus Dose Cohort 1 at 10 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)

    Drug: nab-sirolimus

  • Experimental
    Nab-Sirolimus Dose Cohort 2

    nab-Sirolimus Dose Cohort 2 at 1.0 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)

    Drug: nab-sirolimus

  • Experimental
    Nab-Sirolimus Dose Cohort 3

    nab-Sirolimus Dose Cohort 3 at 2.5 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)

    Drug: nab-sirolimus

  • Experimental
    Nab-Sirolimus Dose Cohort 4

    nab-Sirolimus Dose Cohort 4 at 5.0 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)

    Drug: nab-sirolimus

  • Experimental
    Nab-Sirolimus Dose Cohort 5

    nab-Sirolimus Dose Cohort 5 at 7.5 mg/m2, given once weekly intravenously for 16 weeks. The initial 16-Week treatment was followed optionally by up to 32 weeks of therapy (Extension Part)

    Drug: nab-sirolimus

Interventions

  • nab-sirolimus is an mTOR inhibitor

    Also known as: ABI-009, nab-rapamycin

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicities

    A dose-limiting toxicity (DLT) was defined as a study drug-related Grade ≥3 hematologic AE or persistent intolerable nonhematologic AE of any grade that occurred during the first 4 weeks of treatment, requiring dose reduction or permanent discontinuation of the study drug, in the opinion of the Investigator. The number and percent of patients with a DLT were to be reported by dose cohorts in the Phase 1 dose finding part of the study if any were observed in the study.

    Time frame: 16 weeks

Secondary outcomes

  1. Right Heart Catheterization Based on Central Lab Analysis (Pulmonary Vascular Resistance, Cardiac Output, Cardiac Index, Stroke Volume)

    Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in RHC based on Central Lab Analysis (Pulmonary vascular resistance, Cardiac Output, Cardiac Index, Stroke Volume)

    Time frame: 17 Weeks

  2. 6-minute Walk Distance (6MWD)

    Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in 6MWD

    Time frame: 17 Weeks

  3. N-terminal Pro-brain Natriuretic Peptide (NT Pro-BNP)

    Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in NT Pro-BNP

    Time frame: 17 Weeks

07

Results

Posted Nov 25, 2024
Limitations and caveats
The originally planned dose levels started at 10 mg/m2 weekly nab-sirolimus. While there were no DLTs at the initial dose level (n = 4), based on the totality of AEs and dose reductions, dose levels were modified and patients sequentially enrolled at 1.0, 2.5, 5.0, and 7.5 mg/m2. Given the difficulties with enrollment during the COVID-19 pandemic, the study closed prior to fully enrolling at the last dose level of 7.5 mg/m2 and thus, no Phase 1b cohort expansion occurred at this dose.

Participant flow

16-Week Dose-finding Safety Part
Participant flow — 16-Week Dose-finding Safety Part
MilestoneNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5
Started43431
Completed33421
Not completed10010
Withdrew: Adverse event10000
Withdrew: Covid-19 risk00010
32-Week Optional Extension Part
Participant flow — 32-Week Optional Extension Part
MilestoneNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5
Started01411
Completed01210
Not completed00201
Withdrew: Adverse event00100
Withdrew: Lost to follow-up00101

Outcome measures

PrimaryDose-limiting Toxicities

A dose-limiting toxicity (DLT) was defined as a study drug-related Grade ≥3 hematologic AE or persistent intolerable nonhematologic AE of any grade that occurred during the first 4 weeks of treatment, requiring dose reduction or permanent discontinuation of the study drug, in the opinion of the Investigator. The number and percent of patients with a DLT were to be reported by dose cohorts in the Phase 1 dose finding part of the study if any were observed in the study.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Dose-limiting Toxicities
ParticipantsNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5
Dose-limiting Toxicities00000
SecondaryRight Heart Catheterization Based on Central Lab Analysis (Pulmonary Vascular Resistance, Cardiac Output, Cardiac Index, Stroke Volume)

Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in RHC based on Central Lab Analysis (Pulmonary vascular resistance, Cardiac Output, Cardiac Index, Stroke Volume)

Time frame:
17 Weeks
Reported as:
Median · percentage of change
Right Heart Catheterization Based on Central Lab Analysis (Pulmonary Vascular Resistance, Cardiac Output, Cardiac Index, Stroke Volume)
percentage of changeNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Overall
Pulmonary Vascular Resistance (dyn×sec/cm5)-30.1 (-47.8 to -21.8)10.9 (-20.5 to 18.0)-3.5 (-40.2 to 14.5)-15.7 (-33.3 to 1.9)-30.8 (-30.8 to -30.8)-20.5 (-47.8 to 18.0)
Thermodilution Cardiac Output Mean (L/minute)40.1 (39.5 to 59.6)-15.4 (-23.1 to -13.1)10.8 (-15.6 to 40.1)9.6 (-9.4 to 28.5)27.4 (27.4 to 27.4)16.9 (-23.1 to 59.6)
Cardiac Index (L/minute/m2)40.1 (39.5 to 66.4)-16.5 (-17.4 to -12.8)13.5 (-17.2 to 43.9)9.4 (-5.7 to 24.5)31.2 (31.2 to 31.2)21.4 (-17.4 to 66.4)
Stroke Volume (mL)11.6 (11.1 to 81.1)-14.4 (-19.4 to 10.3)11.0 (-24.6 to 42.3)6.3 (-14.6 to 27.1)10.5 (10.5 to 10.5)10.5 (-24.6 to 81.1)
Secondary6-minute Walk Distance (6MWD)

Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in 6MWD

Time frame:
17 Weeks
Reported as:
Median · percentage of change
6-minute Walk Distance (6MWD)
percentage of changeNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Overall
6-minute Walk Distance (6MWD)-2.0 (-21.0 to 46.6)16.0 (3.1 to 37.8)13.3 (-14.0 to 22.5)16.6 (12.3 to 21.0)21.0 (21.0 to 21.0)15.0 (-21.0 to 46.6)
SecondaryN-terminal Pro-brain Natriuretic Peptide (NT Pro-BNP)

Median Percent Change from Baseline to Week 17 (after 16 weeks of treatment) in NT Pro-BNP

Time frame:
17 Weeks
Reported as:
Median · percentage of change
N-terminal Pro-brain Natriuretic Peptide (NT Pro-BNP)
percentage of changeNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Overall
N-terminal Pro-brain Natriuretic Peptide (NT Pro-BNP)-49.0 (-65.5 to 79.7)-34.6 (-73.8 to -4.5)-7.1 (-62.2 to 18.8)-10.8 (-21.6 to 0.0)-17.0 (-17.0 to -17.0)-19.3 (-73.8 to 79.7)

Adverse events

Collected over Adverse Events reported in the initial 16-Week Treatment for all Cohorts 1,2,3,4 & 5 (ie, from baseline through Week 16). Adverse Events reported in the Optional Extension Phase for up to additional 32 weeks of treatment for Cohorts 2, 3, 4, and 5 (ie, Week 17 through 48).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nab-Sirolimus Dose Cohort 10/4 (0%)1/4 (25%)4/4 (100%)
Nab-Sirolimus Dose Cohort 20/3 (0%)0/3 (0%)3/3 (100%)
Nab-Sirolimus Dose Cohort 30/4 (0%)0/4 (0%)4/4 (100%)
Nab-Sirolimus Dose Cohort 40/3 (0%)1/3 (33.3%)3/3 (100%)
Nab-Sirolimus Dose Cohort 50/1 (0%)0/1 (0%)1/1 (100%)
Overall Nab-Sirolimus Dose Cohort 1-50/15 (0%)2/15 (13.3%)15/15 (100%)
Nab-Sirolimus Dose Cohort 2; 32 Weeks Optional Extension0/1 (0%)0/1 (0%)0/1 (0%)
Nab-Sirolimus Dose Cohort 3; 32 Weeks Optional Extension0/4 (0%)1/4 (25%)4/4 (100%)
Nab-Sirolimus Dose Cohort 4; 32 Weeks Optional Extension0/1 (0%)0/1 (0%)1/1 (100%)
Nab-Sirolimus Dose Cohort 5; 32 Weeks Optional Extension0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Overall Nab-Sirolimus Dose Cohort 1-5Nab-Sirolimus Dose Cohort 2; 32 Weeks Optional ExtensionNab-Sirolimus Dose Cohort 3; 32 Weeks Optional ExtensionNab-Sirolimus Dose Cohort 4; 32 Weeks Optional ExtensionNab-Sirolimus Dose Cohort 5; 32 Weeks Optional Extension
Pneumonia bacterialInfections and infestations0/40/30/41/30/11/150/10/40/10/1
Pneumonia viralInfections and infestations0/40/30/41/30/11/150/10/40/10/1
CellulitisInfections and infestations1/40/30/40/30/11/150/10/40/10/1
Device Related InfectionInfections and infestations0/40/30/40/30/10/150/11/40/10/1
Most frequent other events
Showing 10 of 26
Most frequent other events
EventNab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Overall Nab-Sirolimus Dose Cohort 1-5Nab-Sirolimus Dose Cohort 2; 32 Weeks Optional ExtensionNab-Sirolimus Dose Cohort 3; 32 Weeks Optional ExtensionNab-Sirolimus Dose Cohort 4; 32 Weeks Optional ExtensionNab-Sirolimus Dose Cohort 5; 32 Weeks Optional Extension
NauseaGastrointestinal disorders2/41/30/43/31/17/150/11/40/10/1
HeadacheNervous system disorders2/43/31/42/31/19/150/11/40/10/1
RashSkin and subcutaneous tissue disorders2/41/31/42/31/17/150/10/41/10/1
AlopeciaSkin and subcutaneous tissue disorders0/41/31/40/31/13/150/10/40/10/1
HypertriglyceridemiaMetabolism and nutrition disorders2/41/30/40/31/14/150/10/41/10/1
Dry MouthGastrointestinal disorders0/40/30/41/31/12/150/10/40/10/1
OnychoclasisSkin and subcutaneous tissue disorders0/40/30/40/30/10/150/10/40/11/1
DiarrheaGastrointestinal disorders3/41/31/42/30/17/150/10/40/10/1
InfectionInfections and infestations1/40/31/41/30/13/150/13/40/10/1
FatigueGeneral disorders1/41/31/42/30/15/150/10/40/10/1

Baseline characteristics

The safety analysis set includes all treated patients

Age, Continuous
Age, Continuous(years)Nab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Total
Median56.5 (52 to 69)45 (44 to 63)38.5 (20 to 67)45 (44 to 67)28 (28 to 28)45 (20 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Nab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Total
16-Week Dose-finding Safety Part — Female3343114
16-Week Dose-finding Safety Part — Male100001
32-Week Optional Extension Part — Female014117
32-Week Optional Extension Part — Male000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Total
16-Week Dose-finding Safety Part — Hispanic or Latino011103
16-Week Dose-finding Safety Part — Not Hispanic or Latino4232112
16-Week Dose-finding Safety Part — Unknown or Not Reported000000
32-Week Optional Extension Part — Hispanic or Latino012003
32-Week Optional Extension Part — Not Hispanic or Latino002114
32-Week Optional Extension Part — Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Total
16-Week Dose-finding Part — American Indian or Alaska Native001001
16-Week Dose-finding Part — Asian000000
16-Week Dose-finding Part — Native Hawaiian or Other Pacific Islander000000
16-Week Dose-finding Part — Black or African American000000
16-Week Dose-finding Part — White4333114
16-Week Dose-finding Part — More than one race000000
16-Week Dose-finding Part — Unknown or Not Reported000000
32-Week Optional Extension Part — American Indian or Alaska Native001001
32-Week Optional Extension Part — Asian000000
32-Week Optional Extension Part — Native Hawaiian or Other Pacific Islander000000
32-Week Optional Extension Part — Black or African American000000
32-Week Optional Extension Part — White013116
32-Week Optional Extension Part — More than one race000000
32-Week Optional Extension Part — Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Nab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Total
United States4343115
Body Surface Area
Body Surface Area(m^2)Nab-Sirolimus Dose Cohort 1Nab-Sirolimus Dose Cohort 2Nab-Sirolimus Dose Cohort 3Nab-Sirolimus Dose Cohort 4Nab-Sirolimus Dose Cohort 5Total
16-Week Dose-finding Safety Part2.1 (1.5 to 2.5)1.6 (1.5 to 1.7)1.6 (1.5 to 1.9)1.8 (1.5 to 1.9)1.8 (1.8 to 1.8)1.7 (1.5 to 2.5)
32-Week Optional Extension Part—1.5 (1.5 to 1.5)1.7 (1.5 to 1.9)1.9 (1.9 to 1.9)1.8 (1.8 to 1.8)1.8 (1.5 to 1.9)
08

Study locations

6 sites
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • National Institutes of Health
    Bethesda, Maryland 20892, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Aug 2022, 64 months.

Results were first posted in Nov 2024, 2 years 3 months after primary completion.

Of 21 phase 1 interventional studies under Hypertension, Pulmonary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2015
First posted
Oct 27, 2015
StartActual
Apr 1, 2017
Primary completionActual
Aug 16, 2022
CompletionActual
Sep 16, 2022
Results first posted
Nov 25, 2024
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02587325
Lead sponsor
Aadi Bioscience, Inc.
Responsible party
Sponsor
First posted
Oct 27, 2015
Start date
Apr 1, 2017
Primary completion
Aug 16, 2022
Completion
Sep 16, 2022
Results posted
Nov 25, 2024
Last update
Nov 25, 2024

Study contacts

Marc Simon, MD
principal investigator · University of California, San Francisco

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus Albumin-bound Nanoparticles

Start the discussion